GeneDx Holdings Corp Stock Price, News & Analysis

GeneDx (NASDAQ: WGS) announced on October 14, 2025 that Dr. Mimi Lee, MD, PhD, will join as Chief Precision Medicine Officer to lead the company’s strategy to integrate genomics across the lifespan.

Dr. Lee will advance precision medicine adoption by partnering with policymakers, health systems, biopharma, payers, and advocacy groups, and promote sequencing earlier in life to enable prediction, prevention, and optimized care. She joins from ARPA-H and has senior leadership experience at Samsung Bioepis, Novartis Institutes of Biomedical Research, and BioMarin.

GeneDx (Nasdaq: WGS) will partner with Florida State University and the Florida Institute for Pediatric Rare Diseases to support the Sunshine Genetics Act, a five-year pilot state-backed genomic newborn screening (gNBS) program effective July 1, 2025.

The program aims to offer free, voluntary whole-genome sequencing to newborns at select academic medical centers and hospitals, with a goal to sequence 100,000 newborns. GeneDx will provide end-to-end genomic testing, sequencing, expert interpretation, and clinical reporting, leveraging its record of sequencing nearly 1 million exomes and genomes and prior GUARDIAN-study experience sequencing >17,000 newborns where genome sequencing identified rare disease in 3.2% of cases.

GeneDx (Nasdaq: WGS) launched an Autism Partnership Program on October 9, 2025 to expand access to exome and genome testing, including a dedicated SHANK3 program for Phelan-McDermid syndrome. Jaguar Gene Therapy is the founding partner and will cover testing costs when patients have Medicare/Medicare Advantage and commercial coverage is unavailable. The program targets individuals in the US with moderate-to-severe developmental delay, intellectual disability, ASD, or autistic-like behavior with clinical suspicion of Phelan-McDermid syndrome.

Genetic data from the program will support research and therapy development; cited prevalence estimates include ~0.5%–0.69% of ASD patients with SHANK3 variants (~46,000 US patients).

GeneDx (Nasdaq: WGS) will present research at the American Society of Human Genetics Annual Meeting on October 15–16, 2025 highlighting results enabled by GeneDx Infinity, a dataset of nearly 1 million exomes/genomes and over 7 million phenotypic datapoints. GeneDx will showcase 14 studies across genomic newborn screening, neurodevelopmental disorders, diagnostic technologies, long‑read sequencing validation, and machine learning applications.

Key disclosed results include a study of >62,000 individuals with autism identifying core genes and genetic correlations with other disorders, GUARDIAN gNBS data from 15,000 newborns with high enrollment and follow‑up outcomes, and benchmarking that shows high concordance of CNV detection between exome/genome sequencing and chromosomal microarray.

GeneDx (NASDAQ: WGS) will report Q3 2025 financial results before the market opens on Tuesday, October 28, 2025. Management will host a conference call at 8:30 a.m. Eastern Time the same day to discuss financial and operating results. Investors must register online to access the call. A live and archived webcast will be available in the Events section of the GeneDx investor relations website at https://ir.genedx.com/. The announcement provides timing, registration requirement, and webcast access details for shareholders and analysts.

GeneDx (Nasdaq: WGS) has announced BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the first U.S. multi-state genomic newborn screening initiative, supported by a $14.4 million NIH award.

The initiative, led by Mass General Brigham and Ariadne Labs, will enroll up to 30,000 newborns across 10 states over three years. GeneDx will perform genomic sequencing and interpretation, leveraging their expertise as the company that has diagnosed more children with rare diseases and screened more newborns with genomic sequencing in the U.S.

The project aims to pilot the integration of whole genome sequencing into existing state newborn screening systems, with potential for national scaling. The study will focus on identifying treatable genetic conditions early in life, guided by rare disease advocates, state public health laboratories, and prior research evidence.

GeneDx (Nasdaq: WGS), a leader in genomic insights, has appointed Lisa Gurry as Chief Business Officer (CBO) in a newly-created role. Gurry, a Truveta co-founder and former Microsoft leader, will spearhead GeneDx's transformation by advancing data and information services across biopharma and health systems.

Gurry will leverage GeneDx Infinity™, the company's rare disease dataset containing nearly one million exomes and genomes paired with over seven million phenotypic datapoints. Her responsibilities include overseeing strategic business operations, partnership models, and communications to unlock the dataset's potential for accelerating diagnoses and drug development.

GeneDx (Nasdaq: WGS) announced the introduction of GeneDx Infinity™, its proprietary dataset, at the American Academy of Pediatrics National Conference. Infinity represents the industry's largest rare disease dataset, powering the company's ExomeDx™ and GenomeDx™ testing solutions.

The dataset includes data from over 2.5 million genomic patients, featuring nearly 1 million exomes and genomes, 7 million phenotypic data points, and over 50% non-European representation. GeneDx leads the U.S. clinical exome and genome market with 80% of geneticists choosing the company for superior diagnostic yield.

The announcement follows AAP's recent guidance recommending exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability.

GeneDx (Nasdaq: WGS), a genomic insights company, has appointed Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly, to its board of directors. Dr. Fuchs brings extensive experience in AI and machine learning for diagnostic medicine, having previously served as Dean for AI and Human Health at Mount Sinai and founded multiple companies including Paige AI.

The appointment aligns with GeneDx's AI-driven initiatives, including their recent launch of Multiscore, an AI-powered genetic analysis tool, and the acquisition of Fabric Genomics. These strategic moves strengthen GeneDx's position in using AI to improve rare disease diagnosis and patient outcomes.